Literature DB >> 3557709

Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension.

M D McGoon, R E Vlietstra.   

Abstract

The acute hemodynamic effect of intravenous ketanserin, an S2-serotonergic receptor antagonist, was evaluated during right heart catheterization in 20 patients with primary pulmonary hypertension. Pulmonary and systemic vascular resistance and pressure and cardiac output were measured before and after infusion of low and high dose ketanserin. A small decrease in pulmonary vascular resistance occurred after high dose drug infusion (28.4 to 25.0 U X m2; P less than 0.001), and mean pulmonary arterial pressure was unchanged. Decreases in systemic arterial pressure (91.9 to 85.9 mm Hg; P less than 0.0005) and systemic resistance (46.2 to 38.6 U X m2; P less than 0.001) were more pronounced. Cardiac index increased significantly (2.16 to 2.42 l/min/m2; P less than 0.01) due to reduced ventricular afterload. This study indicates that ketanserin has a small pulmonary vasodilating effect in primary pulmonary hypertension of doubtful clinical significance, similar to conventional vasodilators.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3557709     DOI: 10.1016/0167-5273(87)90200-2

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 3.  GPCRs in pulmonary arterial hypertension: tipping the balance.

Authors:  Jean Iyinikkel; Fiona Murray
Journal:  Br J Pharmacol       Date:  2018-04-17       Impact factor: 8.739

4.  Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn.

Authors:  Cassidy Delaney; Jason Gien; Gates Roe; Nicole Isenberg; Jenai Kailey; Steven H Abman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-19       Impact factor: 5.464

5.  Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans.

Authors:  Hilde Pleym; Guri Greiff; Tom Mjorndal; Roar Stenseth; Alexander Wahba; Olav Spigset
Journal:  J Clin Med Res       Date:  2011-09-26

6.  Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study.

Authors:  Adetoun Sodimu; Sonja Bartolome; Oluwatosin P Igenoza; Kelly M Chin
Journal:  Pulm Circ       Date:  2020-11-25       Impact factor: 3.017

7.  A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2).

Authors:  Howard M Lazarus; Jill Denning; Stephen Wring; Michelle Palacios; Sidra Hoffman; Katelyn Crizer; Watiri Kamau-Kelley; William Symonds; Jeremy Feldman
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.